Slade HB - Search Results

1

Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial.

Mark KE, Corey L, Meng TC, Magaret AS, Huang ML, Selke S, Slade HB, Tyring SK, Warren T, Sacks SL, Leone P, Bergland VA, Wald A. Mark KE, et al. Among authors: slade hb. J Infect Dis. 2007 May 1;195(9):1324-31. doi: 10.1086/513276. Epub 2007 Mar 16. J Infect Dis. 2007. PMID: 17397003 Clinical Trial.

2

Three phase III randomized controlled trials of topical resiquimod 0.01-percent gel to reduce anogenital herpes recurrences.

Mark KE, Spruance S, Kinghorn GR, Sacks SL, Slade HB, Meng TC, Selke S, Magaret A, Wald A. Mark KE, et al. Among authors: slade hb. Antimicrob Agents Chemother. 2014 Sep;58(9):5016-23. doi: 10.1128/AAC.00077-14. Epub 2014 Apr 7. Antimicrob Agents Chemother. 2014. PMID: 24709264 Free PMC article. Clinical Trial.

3

A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod.

Tyring SK, Arany I, Stanley MA, Tomai MA, Miller RL, Smith MH, McDermott DJ, Slade HB. Tyring SK, et al. Among authors: slade hb. J Infect Dis. 1998 Aug;178(2):551-5. doi: 10.1086/517472. J Infect Dis. 1998. PMID: 9697742 Clinical Trial.

4

Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%.

Arany I, Tyring SK, Stanley MA, Tomai MA, Miller RL, Smith MH, McDermott DJ, Slade HB. Arany I, et al. Among authors: slade hb. Antiviral Res. 1999 Aug;43(1):55-63. doi: 10.1016/s0166-3542(99)00033-9. Antiviral Res. 1999. PMID: 10480263 Clinical Trial.

5

Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study.

Quirk C, Gebauer K, De'Ambrosis B, Slade HB, Meng TC. Quirk C, et al. Among authors: slade hb. Cutis. 2010 Jun;85(6):318-24. Cutis. 2010. PMID: 20666194 Clinical Trial.

6

Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts.

Arany I, Tyring SK, Brysk MM, Stanley MA, Tomai MA, Miller RL, Smith MH, McDermott DJ, Slade HB. Arany I, et al. Among authors: slade hb. Antimicrob Agents Chemother. 2000 Jul;44(7):1869-73. doi: 10.1128/AAC.44.7.1869-1873.2000. Antimicrob Agents Chemother. 2000. PMID: 10858346 Free PMC article. Clinical Trial.

7

Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells.

Trauger RJ, Ferre F, Daigle AE, Jensen FC, Moss RB, Mueller SH, Richieri SP, Slade HB, Carlo DJ. Trauger RJ, et al. Among authors: slade hb. J Infect Dis. 1994 Jun;169(6):1256-64. doi: 10.1093/infdis/169.6.1256. J Infect Dis. 1994. PMID: 7910836 Clinical Trial.

8

Imiquimod and genital herpes.

Slade HB, Schacker T, Conant M, Thoming C. Slade HB, et al. Arch Dermatol. 2002 Apr;138(4):534; author reply 534-5. doi: 10.1001/archderm.138.4.534. Arch Dermatol. 2002. PMID: 11939822 No abstract available.

9

Imiquimod applied topically: a novel immune response modifier and new class of drug.

Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Miller RL, et al. Among authors: slade hb. Int J Immunopharmacol. 1999 Jan;21(1):1-14. doi: 10.1016/s0192-0561(98)00068-x. Int J Immunopharmacol. 1999. PMID: 10411278 Review.

10

Imiquimod 5% cream (Aldara).

Slade HB, Owens ML, Tomai MA, Miller RL. Slade HB, et al. Expert Opin Investig Drugs. 1998 Mar;7(3):437-49. doi: 10.1517/13543784.7.3.437. Expert Opin Investig Drugs. 1998. PMID: 15991984

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

63 results

Search Page